2.93 -0.02 (-0.68%)
After hours: 5:21PM EDT
|Bid||2.67 x 3000|
|Ask||3.38 x 3000|
|Day's Range||2.94 - 3.06|
|52 Week Range||2.58 - 5.66|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.58|
On July 13, Achillion Pharmaceuticals’ (ACHN) stock price closed at $3.14, which represents ~22% growth from its 52-week low of $2.58 on February 1. Achillion Pharmaceuticals’ stock price rose 7.17% to $3.14 from the previous day’s closing price of $2.93.
Achillion (ACHN) commences a first-in-human phase I study on ACH-5548, a next-generation, oral small-molecule factor D inhibitor.
Achillion Pharmaceuticals, Inc. (ACHN), a clinical-stage pharmaceutical company focused on developing small molecule inhibitors of factor D in the complement alternative pathway (AP), today announced that the Company had begun dosing healthy volunteer subjects in a first-in-human phase 1 trial of ACH-5548, an oral small-molecule complement factor D inhibitor. ACH-5548 is the third clinical compound discovered and developed by Achillion from its complement factor D platform.
On Friday, June 29, 2018, US markets saw broad based gains with six out of nine sectors finishing the trading sessions in green. All you have to do is sign up today for this free limited time offer by clicking the link below.
Achillion Pharmaceuticals, Inc. (ACHN) announced today that Joseph Truitt, President and Chief Executive Officer of Achillion, will present at the 2018 JMP Securities Life Sciences Conference on Thursday, June 21, 2018, at 9:00 a.m. ET at the St. Regis New York Hotel, in New York, NY. The live audio and subsequent archived webcasts of the Company's presentations will be accessible from the Company's investor relations website, http://ir.achillion.com. The audio recording will be archived for 30 days following the live presentation.
Achillion (ACHN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NEW YORK, June 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SK ...
Losses were broad based as eight out of nine sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Achaogen Inc. (NASDAQ: AKAO), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), and Acorda Therapeutics Inc. (NASDAQ: ACOR).
Achillion Pharmaceuticals, Inc. (ACHN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Barclays revised its view of several smaller mid-cap biotech stocks after the first-quarter earnings season, issuing re-ratings Monday for Prothena Corporation PLC (NASDAQ: PRTA ) and Achillion Pharmaceuticals, ...
Some M&A activity , earnings news flow and clinical trial outcomes helped the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) preserve gains this week. As the earnings season winds down, here're ...
Achillion Pharmaceuticals, Inc. (ACHN), a biopharmaceutical company focused on advancing oral small-molecule factor D inhibitors to modulate the complement alternative pathway for orphan diseases, today announced that two abstracts were accepted for presentation at the 55th European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress being hosted in Copenhagen, Denmark from May 24 – 27, 2018. Abstracts can be accessed on the ERA-EDTA website at http://www.era-edta2018.org/en-US/home.Reprints of the oral and poster presentations will be available following their presentation under the resources section of the Achillion website at http://www.achillion.com.
LONDON, UK / ACCESSWIRE / May 4, 2018 / If you want access to our free research report on Esperion Therapeutics, Inc. (NASDAQ: ESPR) all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ESPR as the Company's latest news hit the wire. On May 2, 2018, the Company announced positive top-line results from the second pivotal, Phase-3 study (Study 1/1002-040) the long-term safety study, evaluating the safety, tolerability, and efficacy of bempedoic acid versus placebo in high-risk patients with atherosclerotic cardiovascular disease (ASCVD) who are inadequately controlled with current lipid-modifying therapies, including maximally tolerated statin therapy. Active-Investors.com is currently working on the research report for Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), which also belongs to the Healthcare sector as the Company Esperion Therapeutics.
Achillion Pharmaceuticals, Inc. (ACHN) announced today that Joseph Truitt, President and Chief Executive Officer of Achillion, will present a corporate overview at the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8, 2018, at 9:20 a.m. ET at the Intercontinental Boston Hotel, Boston, MA. The live audio and subsequent archived webcasts of the Company's presentations will be accessible from the Company's investor relations website, http://ir.achillion.com.
Achillion Pharmaceuticals (ACHN) disappoints with wider-than-expected loss in the first quarter. Appoints Joseph Truitt as new CEO.
The New Haven, Connecticut-based company said it had a loss of 15 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
Achillion Pharmaceuticals, Inc. (ACHN), a biopharmaceutical company focused on advancing oral small-molecule factor D inhibitors to modulate the complement alternative pathway, today reported financial results for the three months ended March 31, 2018. For the first quarter of 2018, the Company reported a net loss of $20.6 million or $0.15 per share, compared with a net loss of $20.2 million or $0.15 per share for the first quarter of 2017. Cash, cash equivalents, marketable securities and interest receivable as of March 31, 2018 were $308.4 million.
Investors in Achillion Pharmaceuticals (ACHN) need to pay close attention to the stock based on moves in the options market lately.
There are plenty of opportunities to invest in healthcare stocks, as there are thousands of companies, ranging from big and well-established pharmaceuticals that also pay substantial dividends, to small, emerging companies without any products on the market or revenue, but backed by their research into novelty therapies for various illnesses. When looking for healthcare stocks […]